ArticleFrontiers in neurology
Lipid feature and late onset ≥80 years of ischemic stroke: a retrospective study in lipid-lowering therapy-naive adults.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The population of patients with first-onset ischemic stroke at or above the age of 80 is steadily growing. However, the distinct lipid profile characteristics of this oldest-old cohort remain systematically undefined. This study aimed to delineate these lipid patterns and elucidate their association with the late onset of acute ischemic stroke in advanced age. Methods: We conducted a retrospective cohort analysis of patients with first-ever acute ischemic stroke consecutively enrolled between March 2022 and June 2025. To mitigate confounding by lipid-lowering therapies, a critical modifier of both lipid metabolism and cerebrovascular risk, we implemented strict exclusion criteria for any prior exposure to cholesterol-modulating agents. Participants were stratified into three age groups: youngest-old (60-69 years), middle-old (70-79 years), and oldest-old (≥80 years). Demographic characteristics and lipid parameters were systematically analyzed across groups, with correlation and multivariate regression analyses performed to identify lipid-related predictors of late-onset ischemic stroke. Results: A total of 565 patients were included in the final analysis based on our inclusion and exclusion criteria (239 youngest-old; 200 middle-old; 126 oldest-old). The oldest-old group exhibited significantly lower levels of total cholesterol, triglycerides, apolipoprotein B, low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and reduced LDL-C/HDL-C and VLDL-C/HDL-C ratios compared to younger cohorts (all Conclusion: The findings suggest a distinct lipid profile in older adults with late-onset ischemic stroke. A key implication for management is that non-HDL-C should be elevated to a co-primary target alongside LDL-C in public health strategies for lipid control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.